AUS
NZ
UK
CA
USA
IND
Highlights
- EBR Systems (ASX:EBR) anticipates FDA approval for its Wise pacemaker lead by April 13, paving the way for commercial launch in late 2023.
- Cogstate (ASX:CGS) reports a 19% increase in revenue due to improved US biotech funding, particularly benefiting Alzheimer’s trials.
- Percheron Therapeutics (ASX:PER) experiences investor tension following the disappointing DMD trial results, while seeking new clinical opportunities.
EBR Systems
EBR Systems (ASX:EBR) is on the cusp of a significant breakthrough with its Wise wireless pacemaker lead, awaiting potential US FDA approval by April 13. Following a successful pre-marketing inspection by the FDA, EBR is preparing for a commercial release in the latter half of 2023. This innovative technology is set to transform cardiac resynchronization therapy by eliminating traditional coronary sinus leads. Future advancements promise to extend wireless endocardial stimulation to other cardiac and non-cardiac applications.
EBR's chief, John McCutcheon, expressed confidence in the company's manufacturing practices, following rigorous audits by the FDA. Furthermore, Wise has been recognized as part of the Centers for Medicare and Medicaid Services program, facilitating faster national reimbursement coverage due to its breakthrough status.
Cogstate
Cogstate (ASX:CGS), a leader in brain monitoring technology, has experienced a substantial 19% revenue boost in the December half, amounting to USD 23.9 million. This surge is attributed to enhanced funding conditions in the US biotech sector, particularly supporting neurological clinical trials. Notably, Alzheimer’s studies have significantly augmented revenues, with diversification into trials concerning pediatric and rare diseases.
The company has secured new trial contracts worth USD 20.3 million, showcasing an 86% growth. Despite changes in the US health administration, the potential for growth in clinical trials remains robust. Cogstate continues to uphold consistent profit margins, emphasizing its strategic focus on expanding clinical trial services.
Percheron Therapeutics
Percheron Therapeutics (ASX:PER) is undergoing a period of strategic reassessment following the phase IIb trial failure of its DMD drug candidate, avicursen (ATL1102), which missed secondary endpoints. This has triggered corporate turmoil, with a faction of investors seeking leadership changes. Despite these challenges, Percheron is diligently analyzing trial data to explore viable paths forward.
With USD 8 million in cash reserves as of September 2024, Percheron is actively seeking new clinical programs and potential partnerships to restore shareholder value. Company leadership remains committed to adapting and reorienting its business strategy to address these challenges and explore alternative drug development opportunities.
The healthcare sector continues to witness significant technological advances despite challenges, as demonstrated by EBR Systems’ novel wireless pacemaker technology, Cogstate’s expanding clinical trial revenues, and Percheron Therapeutics’ strategic pivot post-trial setback. These developments reflect a dynamic landscape where innovation and adaptation are vital for sustained growth and success.
